Discontinue Finasteride Immediately
If a male patient continues taking finasteride 1 mg despite developing gynecomastia and erectile dysfunction, these adverse effects will likely persist and may become permanent, significantly impacting his quality of life. The drug should be stopped immediately upon recognition of these side effects.
What Happens With Continued Use
Sexual Dysfunction Persistence and Worsening
The evidence clearly demonstrates that continuing finasteride in the presence of erectile dysfunction carries significant risks:
Sexual dysfunction may become permanent even after drug discontinuation 1, 2. Postmarketing surveillance has documented cases where erectile dysfunction, decreased libido, and ejaculation disorders continued after stopping finasteride 1.
The FDA drug label explicitly warns of "sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, decreased libido and ejaculation disorders" 1.
While guideline data from the ASCO/AUA suggests sexual dysfunction "decreased over time" during continued treatment 3, this refers to population averages—not individual patients who have already developed symptoms. The magnitude of dysfunction was modest in trials (mean 3.21 points on a 0-100 scale), but this does not apply to symptomatic individuals.
Gynecomastia Becomes Irreversible
Continuing finasteride with established gynecomastia risks permanent breast tissue changes:
Gynecomastia can become fibrotic and irreversible with continued exposure 4. One case report documented persistent gynecomastia that failed to resolve even after 6 months of raloxifene treatment and ultimately required bilateral mammoplasty 4.
The risk of gynecomastia is consistently elevated with 5α-reductase inhibitors, with a 2-4% absolute increase over placebo 3. Recent large-scale data shows a 55% increased risk (RR 1.55) 5.
Early intervention is critical—once fibrosis develops, medical management fails and surgical removal becomes the only option 4.
Critical Clinical Pitfalls
The "Wait and See" Approach is Wrong
Many clinicians mistakenly believe side effects will resolve with continued treatment. This is dangerous misinformation. While population-level data shows some improvement over time 3, individual patients with established symptoms face:
- Risk of permanent sexual dysfunction 1, 2
- Progressive gynecomastia requiring surgery 4
- Potential psychological sequelae including depression 2
Underreporting Creates False Reassurance
Only 8 cases of gynecomastia with 1 mg finasteride were reported between 1997-2009 4, yet recent database analysis of over 550,000 patients shows significantly higher rates 5. This massive underreporting means patients are inadequately informed of true risks.
Immediate Management Algorithm
Stop finasteride immediately—do not continue even one more dose
Document baseline severity of both gynecomastia and erectile dysfunction
Counsel patient that symptoms may persist for weeks to months, or potentially permanently
Monitor for resolution:
For gynecomastia management:
- If present <6 months and no fibrosis: consider raloxifene trial
- If fibrotic or persistent >6 months: refer to surgery 4
For erectile dysfunction:
The Bottom Line
Continuing finasteride in the presence of symptomatic gynecomastia and erectile dysfunction prioritizes hair preservation over sexual function and physical appearance—an unacceptable trade-off for quality of life. The patient has already demonstrated susceptibility to these adverse effects, and continued exposure risks permanent complications that may require surgical intervention and cause lasting psychological harm.